Skip to main content
Equibles

ExodusPoint Capital Management, LP

Position in RNA — Atrium Therapeutics, Inc.

CIK 1736225 NEW YORK, NY
Back to RNA Full portfolio

Position in RNA

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,577,348
+$541,949 QoQ
Shares Held
117,275
+51.4% QoQ
Ownership
0.686%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#33
of 154 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RNA Over Time

Shares Held

Position Value (USD)

Derivatives in RNA

reported options exposure · as of Mar 31, 2026
CallValue
$0
CallShares
0
PutValue
$140,385
PutShares
10,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ExodusPoint Capital Management, LP holds $280,525,216 across 101 Biotechnology names. RNA ranks #47 (0.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 CYTK
Cytokinetics Inc
 249,259 $21,234,374
2 BBIO
BridgeBio Pharma, Inc.
 224,927 $16,752,562
3 ORKA
Oruka Therapeutics, Inc.
 148,212 $14,105,336
4 VKTX
Viking Therapeutics, Inc.
 361,126 $14,087,525
5 JAZZ
Jazz Pharmaceuticals plc
 53,201 $12,819,844
6 NAMS
NewAmsterdam Pharma Co N.V.
 304,334 $10,313,879
7 TGTX
Tg Therapeutics, Inc.
 164,513 $9,038,344
8 DNLI
Denali Therapeutics Inc.
 336,567 $8,656,503

All Filings in RNA

Export CSV
3 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,577,348 117,275
2026-03-31 $140,385 10,500
2026-03-31 $1,035,399 77,442